Cytokine Adsorption for Neurotoxicity in CAR-T Therapy
Author Information
Author(s): Alix Buhlmann, Emanuel Rom, Giovanna Schweiger, Dominik Schneidawind, Sascha David
Primary Institution: University Hospital Zurich
Hypothesis
Can extracorporeal cytokine adsorption effectively treat immune effector cell-associated neurotoxicity syndrome in patients receiving CAR-T therapy?
Conclusion
The use of extracorporeal cytokine adsorption led to a full recovery of a patient suffering from immune effector cell-associated neurotoxicity syndrome.
Supporting Evidence
- The patient showed a significant reduction in IL-6 levels after treatment.
- The patient was off vasopressors within 12 hours after starting the treatment.
- The patient's neurological status improved significantly within days.
Takeaway
Doctors used a special machine to clean the blood of a patient who was very sick after cancer treatment, and it helped the patient get better.
Methodology
Extracorporeal cytokine adsorption was used in conjunction with continuous renal replacement therapy in a critically ill patient.
Potential Biases
The improvement may reflect the natural course of the disease or a delayed steroid effect.
Limitations
This is a single case report, and the uncontrolled nature of the study limits the ability to draw definitive conclusions.
Participant Demographics
A 65-year-old male patient with refractory diffuse large B-cell lymphoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website